News

Free Webinar Planned for Those Interested in Referring or Applying to NIH Undiagnosed Diseases Network


 

References

The Undiagnosed Diseases Network (UDN), a research project supported by the National Institutes of Health (NIH) Common Fund, brings together clinical and research experts from across the country to try to solve the most challenging medical mysteries. As part of this project, patients with longstanding unexplained symptoms can apply to receive an in-depth clinical and research examination at one of the UDN’s seven medical centers.

The National Organization for Rare Disorders (NORD) and the UDN will co-host a free webinar from 1 to 2 p.m. ET on Friday, June 3, for clinicians, researchers, and patients that will provide an overview of the UDN, discuss the application and evaluation process, and review financial considerations. Participants will also have the opportunity to hear from a patient who has been through the UDN clinical and research evaluation.

Speakers will include Katrina Dipple, MD, PhD, Departments of Human Genetics and Pediatrics, University of California, Los Angeles; Vandana Shashi, MD, Department of Pediatrics, Duke University Medical Center; Kimberly Splinter, MS, CGC, Genetic Counselor and Clinical Project Manager, UDN Coordinating Center, Harvard Medical School.

Register here for this free webinar. Questions may be directed to education@rarediseases.org.

Recommended Reading

Free Summer Camp For Families of Children With Rare Diseases
MDedge Family Medicine
NORD Speaks on Behalf of Continued Funding for NIH Undiagnosed Diseases Network
MDedge Family Medicine
NIH and FDA Release a Draft Clinical Trial Protocol Template for Public Discussion
MDedge Family Medicine
News From NORD Round-Up: April 2016
MDedge Family Medicine
Superhigh ferritin spells trouble in macrophage activation syndrome
MDedge Family Medicine
Large placebo effect seen in trial of maralixibat for primary biliary cholangitis
MDedge Family Medicine
TSH antibody levels predict Graves relapse after thionamides
MDedge Family Medicine
Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis
MDedge Family Medicine
FDA: Olanzapine can cause serious skin reaction
MDedge Family Medicine
Study lays groundwork for refractory cutaneous lupus treatment algorithms
MDedge Family Medicine